drugset / Trial / NCT06356714
Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the efficacy and safety of Nocardia rubra cell wall skeleton in combination with prior second- or third-line regimens for the treatment of potentially hazardous colorectal cancer SD(Stable Disease) status in the real world.
Timeline
- Start
- 2025-03-15
- Primary completion
- 2026-09-24
- Completion
- 2027-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nocardia Rubra Cell Wall Skeleton | Unknown | 200 ug | Subcutaneous |
| Subject | Nocardia Rubra Cell Wall Skeleton | Unknown | 400 ug | Subcutaneous |